Hernández-Espinosa David, Ordóñez Adriana, Vicente Vicente, Corral Javier
Department of Medicine, Centro Regional de Hemodonación, University of Murcia, Murcia, Spain.
Thromb Haemost. 2007 Sep;98(3):557-63.
Serpins are key actors of systems involving proteolytic reactions, such as the haemostatic system, as they are irreversible suicide inhibitors of serine proteases. The structural flexibility and physical properties of serpins that are required for their efficient inhibitory mechanism also make them especially vulnerable to even minor factors that induce conformational changes in the native form of these molecules, leading to a number of inactive conformations, such as latent, cleaved or polymers. Increasing numbers of conformational mutations affecting haemostatic serpins, mainly antithrombin, the main endogenous anticoagulant, have been described. These mutations cause circulating deficiencies of the molecules, in most cases due to intracellular retention, which may be associated with a hyper-coagulable state. Indeed, conformational mutations in antithrombin have been identified in patients with severe venous thrombosis, which has led to the hypothesis that these disorders might be included in the group of conformational diseases. Moreover, we have recently demonstrated that other factors, including both drugs, such as the treatment with L-asparaginase, or environmental factors, such as high temperatures or hyperlipidemia, may also have conformational consequences on hepatic antithrombin, thus resulting in intracellular aggregation and plasma deficiency, which may increase the risk of thrombosis. In this study, we review the causes of deficiency of haemostatic serpins that may be explained by conformational mechanisms, and their association with an increased risk of venous thrombosis.
丝氨酸蛋白酶抑制剂(Serpins)是涉及蛋白水解反应系统的关键参与者,如止血系统,因为它们是丝氨酸蛋白酶的不可逆自杀性抑制剂。丝氨酸蛋白酶抑制剂高效抑制机制所需的结构灵活性和物理特性,也使它们特别容易受到一些微小因素的影响,这些因素会导致这些分子天然形式的构象变化,从而产生许多无活性的构象,如潜伏型、裂解型或聚合物型。越来越多影响止血性丝氨酸蛋白酶抑制剂的构象突变被描述,主要是抗凝血酶,它是主要的内源性抗凝剂。这些突变导致分子在循环中的缺乏,在大多数情况下是由于细胞内滞留,这可能与高凝状态有关。事实上,在严重静脉血栓形成患者中已鉴定出抗凝血酶的构象突变,这导致了一种假说,即这些疾病可能属于构象性疾病。此外,我们最近证明,其他因素,包括药物,如用L-天冬酰胺酶治疗,或环境因素,如高温或高脂血症,也可能对肝脏抗凝血酶产生构象影响,从而导致细胞内聚集和血浆缺乏,这可能增加血栓形成的风险。在本研究中,我们回顾了可能由构象机制解释的止血性丝氨酸蛋白酶抑制剂缺乏的原因,以及它们与静脉血栓形成风险增加的关联。